header logo image

Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs

November 30th, 2020 7:57 am

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided updates regarding the statistical analysis plan for the ongoing Phase 3 trial of OTIVIDEX in Ménière’s disease, and outlined plans for a Phase 2 trial of OTO-313 in tinnitus.

Go here to read the rest:
Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick